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Candida haemulonii, Candida haemulonii var. vulnera and Candida duobushaemulonii,
which form the C. haemulonii complex, are emerging etiologic agents of fungal infections
known to be resistant to the most commonly used antifungals. The well-established
anti-Candida potential of metal complexes containing 1,10-phenanthroline (phen) ligands
encouraged us to evaluate different copper(II), manganese(II), and silver(I) phen chelates
for their ability to inhibit planktonic growth and biofilm of C. haemulonii species
complex. Two novel coordination complexes, {[Cu(3,6,9-tdda)(phen)2].3H2O.EtOH}n
and [Ag2(3,6,9-tdda)(phen)4].EtOH (3,6,9-tddaH2 = 3,6,9-trioxaundecanedioic acid),
were synthesized in a similar fashion to the other, previously documented, sixteen
copper(II), manganese(II), and silver(I) chelates employed herein. Three isolates of each
C. haemulonii species complex were used and the effect of the metal chelates on viability
was determined utilizing the CLSI standard protocol and on biofilm-growing cells using
the XTT assay. Cytotoxicity of the chelates was evaluated by the MTT assay, employing
lung epithelial cells. The majority of the metal chelates were capable of interfering with the
viability of planktonic-growing cells of all the fungal isolates. The silver complexes were
the most effective drugs (overall geometric mean of the minimum inhibitory concentration
(GM-MIC) ranged from 0.26 to 2.16 µM), followed by the manganese (overall GM-MIC
ranged from 0.87 to 10.71 µM) and copper (overall GM-MIC ranged from 3.37 to
>72 µM) chelates. The manganese chelates (CC50 values ranged from 234.51 to
>512 µM) were the least toxic to the mammalian cells, followed by the silver (CC50
values ranged from 2.07 to 13.63 µM) and copper (CC50 values ranged from 0.53
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to 3.86 µM) compounds. When tested against mature biofilms, the chelates were
less active, with MICs ranging from 2- to 33-fold higher levels when compared to the
planktonic MIC counterparts. Importantly, manganese(II), copper(II), and silver(I) phen
chelates are relatively cheap and easy to synthesize and they offer significant antifungal
chemotherapeutic potential for the treatment of highly resistant pathogens.
Keywords: Candida haemulonii complex, metal-based drugs, 1,10-phenanthroline, antifungal activity, anti-
virulence, biofilm
INTRODUCTION
The global incidences of invasive candidiasis has increased
considerably in recent decades, being the fourth and sixth
leading cause of nosocomial blood infections in the United
States of America and Europe, respectively (Caggiano et al.,
2015). New advances in medicine have improved the survival
rates of innumerous patients, but also resulted in an augment
in the number of immunocompromised individuals, who are
extremely susceptible to systemic mycoses (Richardson and
Lass-Flörl, 2008; Sanguinetti et al., 2015). Infections caused
by non-albicans Candida species, such as Candida parapsilosis,
Candida glabrata, Candida tropicalis, and Candida krusei,
are becoming increasingly more common in hospital settings
(Abu-Elteen and Hamad, 2012; Ramos et al., 2015). This
new scenario constitutes a clinical challenge, since such non-
albicans Candida species are more resistant to the different
classes of antifungal drugs that are currently available (Abu-
Elteen and Hamad, 2012; Ramos et al., 2015). This trend
is also being observed for fungal infections caused by other
uncommon species such as those belonging to the Candida
haemulonii complex (C. haemulonii, Candida duobushaemulonii
and Candida haemulonii var. vulnera). The risk or predisposing
factors associated with fungemia caused by C. haemulonii
complex include mechanic ventilation, serious conditions such
as cancer and immunodeficiency and the use of central venous
catheters (Almeida et al., 2012; Cendejas-Bueno et al., 2012;
Muro et al., 2012). Given the epidemiological profile of the
C. haemulonii complex and the fact that it is resistant to
such a broad spectrum of the state-of-the-art antifungals
(e.g., amphotericin B, flucytosine, fluconazole, itraconazole,
voriconazole, micafungin, and caspofungin) (Giusiano et al.,
2005; Khan et al., 2007; Kim et al., 2009; Ruan et al.,
2010), it is imperative that the scientific community examine
alternative therapeutic paths for it treatment. Aggravating this
scenario, recently, our research group described the ability
of C. haemulonii species complex to form biofilm on inert
substrate (Ramos et al., 2017). From a medical viewpoint,
the microbial biofilm architecture is a complex and robust
structure, which is extremely resistant to different classes of drugs
(e.g., antifungals and disinfectants), host immune attack (e.g.,
antibodies, antimicrobial peptides, and complement proteins)
and several hostile environmental stressors (e.g., dehydration and
radiation; Nett, 2014; Ramage et al., 2014; Mello et al., 2017).
Anti-biofilm strategies able to prevent and/or eradicate fungal
biofilms in medical devices are urgently required (Ramage et al.,
2014; Ramos et al., 2017).
The anti-Candida activity of transition metal chelates
containing 1,10-phenanthroline (phen) ligands is already well-
established, and it is known that copper(II)-, manganese(II)-, and
silver(I)-phen chelates are potent growth inhibitors ofC. albicans,
C. glabrata, C. tropicalis, and C. krusei (Geraghty et al., 2000;
McCann et al., 2000, 2012; Coyle et al., 2003). These compounds
affected mitochondrial function, reduced cytochrome b and c
synthesis, induced respiratory uncoupling and increased cell wall
permeability in the fungal cells (McCann et al., 2004; Creaven
et al., 2007). Given the proven anti-Candida profile of phen-
based drugs, we decided to examine the anti-C. haemulonii
species complex therapeutic potential of a series of copper(II),
manganese(II), and silver(I) phen chelates on both planktonic
growth and biofilm of nine Brazilian clinical isolates of the
C. haemulonii complex. The hypothesis of our study is based on
the premise that clinical isolates belonging to the C. haemulonii
complex often exhibit resistance to different classes of antifungal
agents commonly used in medical practice and, therefore, there
is an urgent need to find new active compounds against these
emerging fungal species.
MATERIALS AND METHODS
Chemistry
Chemicals were purchased from commercial sources and used
as received without further purification. Infrared (IR) spectra
were recorded in the region 4,000–370 cm−1 on a Perkin
Elmer System 2000 FT spectrometer and using anhydrous
potassium bromide to form solid KBr discs. Elemental analysis
(CHN) was carried out for all the complexes using a FLASH
EA 1112 Series Elemental Analyser with Eager 300 operating
software. Room temperature, solid state magnetic susceptibility
measurements for the Cu(II) compounds, [Cu(3,6,9-tdda)].H2O
and {[Cu(3,6,9-tdda)(phen)2].3H2O.EtOH}n (7), were
made using a Johnson Matthey Magnetic Susceptibility
Balance.
The following metal chelates were prepared using
previously published methods: [Cu(ph)(phen)(H2O)2]
(1) (phH2 = phthalic acid) (Kellett et al.,
2012); [Cu(ph)(phen)2].3H2O.2EtOH (2) (Kellett
et al., 2011); [Cu(isoph)(phen)2].6H2O.EtOH (3)
(isophH2 = isophthalic acid) (Kellett et al., 2011);
[{Cu(phen)2}2(terph)](terph).13.5H2O.2EtOH (4)
(terphH2 = terephthalic acid) (Kellett et al.,
2011); [Cu2(oda)(phen)4](ClO4)2.2.76H2O.EtOH (5)
(odaH2 = octanedioic acid) (Devereux et al., 1999);
[Cu(phendione)3](ClO4)2.4H2O (6) (phendione =
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1,10-phenanthroline-5,6-dione) (McCann et al., 2004);
[Mn(ph)(phen)(H2O)2] (8) (Devereux et al., 2000);
[Mn(ph)(phen)2(H2O)].4H2O (9) (Devereux et al., 1999);
[Mn2(isoph)2(phen)3].4H2O (10) (Devereux et al., 2000);
{[Mn(phen)2(H2O)2]}2(isoph)2(phen).12H2O (11) (Devereux
et al., 2000); [Mn(tereph)(phen)2].5H2O (12) (Leon, 2000);
[Mn2(oda)(phen)4(H2O)2][Mn2(oda)(phen)4(oda)2].4H2O (13)
(Casey et al., 1994); {[Mn(3,6,9-tdda)(phen)2].3H2O.EtOH}n
(14) (3,6,9-tddaH2 = 3,6,9-trioxaundecanedioic acid) (McCann
et al., 1997); [Ag(phendione)2]ClO4 (15) (McCann et al.,
2004); [Ag(phen)2]ClO4 (17) (McCann et al., 2004) and
[Ag2(phen)3(udda)].3H2O (18) (uddaH2 = undecanedioic
acid) (Thornton et al., 2016). The novel complexes,
{[Cu(3,6,9-tdda)(phen)2].3H2O.EtOH}n (7) and [Ag2(3,6,9-
tdda)(phen)4].EtOH (16), were synthesized using the two-step
procedures outlined below. The preparation of all silver
compounds was conducted in the absence of light and the
products were stored in the dark.
{[Cu(3,6,9-tdda)(phen)2].3H2O.EtOH}n (7). Step (i):
Copper(II) acetate hydrate (1.50 g; 7.51 mmol) was dissolved
in ethanol (50 mL) and the solution was added to an ethanolic
solution (25 mL) of 3,6,9-trioxaundecanedioic acid (3,6,9-
tddaH2) (2.84 g; 8.95 mmol). The light-green suspension was
refluxed for 1 h, and after cooling to room temperature the
light-green solid, [Cu(3,6,9-tdda)].H2O, was filtered off, washed
with cold ethanol and air dried. Yield: 1.88 g (82.97%). %
Calculated: C: 31.84, H: 4.68. % Found: C: 32.20, H: 4.60. IR
(KBr) νmax: 3280, 2930, 1585, 1430, 1330, 1250, 1130, 1090,
1055, 965, 920, 840, 720, 475 cm−1. µeff: 1.93 B.M. Solubility:
soluble in H2O, MeOH, EtOH and insoluble in CHCl3, ethyl
acetate and acetone. Step (ii): [Cu(3,6,9-tdda)].H2O (1.00 g; 3.31
mmol) and phen (2.39 g; 13.26 mmol) were dissolved together
in ethanol (50 mL) and the resulting dark-green mixture was
refluxed for 2 h. The suspension was cooled and the green solid,
{[Cu(3,6,9-tdda)(phen)2]3H2O.EtOH}n(7), was filtered off,
washed with cold ethanol and air dried. Yield: 1.63 g (66.09%).
% Calculated: C: 54.87, H: 5.42, N: 7.53. % Found: C: 54.65, H:
5.63, N: 7.39. IR (KBr) νmax: 3982, 3415, 3041, 2901, 1989, 1752,
1618, 1587, 1513, 1421, 1320, 1252, 1221, 1121, 1090, 1077, 1011,
934, 893, 847, 770, 720, 704, 643, 619, 603, 573, 555, 507, 426
cm−1. µeff: 1.92 B.M. Solubility: soluble in H2O, MeOH, EtOH
and insoluble in ethyl acetate and acetone.
[Ag2(3,6,9-tdda)(phen)4].EtOH (16). Step (i): Silver(I)
acetate (3.00 g; 17.97 mmol) was dissolved in ethanol (30 mL)
and the solution was added to an ethanolic solution (25 mL)
of 3,6,9-trioxaundecanedioic acid (3,6,9-tddaH2) (2.84 g; 8.95
mmol) and the orange-brown suspension refluxed for 3 h.
After cooling to room temperature, the light orange-brown
powder, [Ag2(3,6,9-tdda].2H2O, was filtered off, washed with
cold ethanol and then air dried. Yield: 3.79 g (44.69%). %
Calculated: C: 20.36, H: 2.56. % Found: C: 20.34, H: 2.51. IR
(KBr) νmax: 3425, 2896, 1614, 1406, 1116 cm
−1. 1H NMR: (D2O)
δ = 3.81 (s, 4H), 3.56 (s, 8H). Solubility: soluble in hot H2O
and hot DMSO. Step (ii): [Ag2(3,6,9-tdda].2H2O (0.50 g; 1.06
mmol) and phen (0.827 g; 4.589 mmol) were dissolved together
in ethanol (40 mL) and the mixture refluxed overnight. After
cooling to room temperature the mixture was placed in an ice
bath. Green [Ag2(3,6,9-tdda)(phen)4].EtOH (16) precipitated
and was filtered off, washed with cold ethanol and air dried.
Yield: 0.83 g (65.10%). % Calculated: C: 57.92, H: 4.19, N: 9.32.
% Found: C: 57.75, H: 5.16, N: 9.02. IR (KBr) νmax: 3380, 3046,
2905, 1978, 1804, 1618, 1585, 1509, 1421, 1322, 1263, 1215, 1121,
1077, 1018, 932, 890, 838, 726, 621, 465, 413 cm−1. 1H NMR
(500 MHz, DMSO-d6, 313 K, TMS) δ= 9.12(8H, s), 8.63 (8H, d),
8.08 (8H, s), 7.91 (8H, dd), 3.74 (4H, s), 3.57 (8H, dd). 13C NMR
(125 MHz, DMSO-d6, 313 K, TMS) δ = 173.41, 151.28, 143.57,
138.03, 129.24, 127.37, 124.74, 71.44, 70.42, 69.74. Solubility:
soluble in H2O, MeOH, EtOH and insoluble in ethyl acetate and
acetone.
Epithelial Cell Lineage and
Microorganisms’ Growth Conditions
Three clinical isolates of each species that form the C. haemulonii
complex were used in this study: C. haemulonii (LIPCh4
from finger nail, LIPCh7 from toe nail, and LIPCh12 from
blood), C. duobushaemulonii (LIPCh1 from finger nail, LIPCh6
from toe nail, and LIPCh8 from blood) and C. haemulonii
var. vulnera (LIPCh5 from toe nail, LIPCh9 from urine, and
LIPCh11 from blood) (Ramos et al., 2015). The fungal isolates
were identified by the automatized system VITEK R© 2 and
then characterized by ITS1-5.8S-ITS2 gene sequencing (Ramos
et al., 2015). Fungal cells were cultured in Sabouraud-dextrose
medium under constant agitation (130 rpm) for 48 h at 37◦C.
Human lung adenocarcinoma A549 cells were maintained
in culture flasks containing DMEM medium supplemented
with 10% fetal bovine serum at 37◦C in an atmosphere of
5% CO2.
Effects of Test Compounds on Planktonic
Fungal Growth
Susceptibility profile assays were performed in accordance with
the broth microdilution protocol described in the document
M27-A3 published by the Clinical and Laboratory Standards
Institutes (CLSI, 2008). Samples of the test chelates were
dissolved in DMSO (500 µL) and then serially diluted in
a 96-well plate containing RPMI 1640 (Sigma-Aldrich, USA)
to give the concentration range of 0.0625-32 mg/L. Aqueous
solutions of the metal-free phen ligand and the simple metal
salts, MnCl2, CuCl2, and AgNO3, were also screened over the
same concentration range. Caspofungin (Sigma-Aldrich) was
used as a classical antifungal agent able to block the growth
of all clinical isolates of C. haemulonii species as previously
reported by our research group (Ramos et al., 2015). Water
dilutions containing DMSO concentrations corresponding to
those used to prepare the drug solutions were assessed in parallel.
Untreated and compound-treated fungal cells were incubated at
37◦C for 48 h and the minimal inhibitory concentration (MIC)
was established as the lowest compound concentration where
no cellular growth could be detected by visual inspection in
accordance to the CLSI recommendation. The geometric mean
of the MIC values (GM-MIC) of each compound against all the
fungal isolates was calculated using the software, Microsoft Office
Excel 2013.
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Mammalian Cell Toxicity Assay and
Determination of Selectivity Indexes
The cytotoxicity was evaluated using the MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide]
(Sigma-Aldrich) assay (Mosmann, 1983). A549 cells (104)
were seeded into tissue culture plates (TPP, Switzerland) and
cultured for 24 h at 37◦C in a 5% CO2 in order to obtain
cellular confluence. The wells were then washed twice with
DMEM to remove non-adherent cells and the test compounds
were added (in concentrations ranging from 0.0313 to 512
µg/mL) to plates containing DMEM, followed by a 48 h
incubation period under the same conditions mentioned
above. The cellular viability was evaluated by adding MTT
to each well and incubating the plates in the dark for 3 h,
allowing the viable cells containing active mitochondrial
dehydrogenase enzymes to metabolize MTT-tetrazolium salt
into purple formazan. The formazan crystals were then dissolved
in DMSO (100 µL) and the absorbance (450 nm) measured
using a Thermomax Molecular Device microplate reader. The
concentration capable of reducing cellular viability by 50%
(CC50) was calculated, and the selectivity index (SI) determined
using the following equation: A549 CC50/C. haemulonii complex
GM-MIC.
Effects of Test Compounds on
Biofilm-Growing Cells
The effect of the compounds on biofilm-growing cells was
determined using the previously described microtiter-based
technique (Ramage et al., 2001). The fungi (106 yeast cells) were
incubated for 48 h at 37◦C in 96-well polystyrene microtiter
plates (Corning R©, Corning Incorporated, USA) containing
Sabouraud-dextrose broth to accommodate biofilm formation.
Following biofilm formation, the culture medium was aspirated
and non-adherent cells removed by thoroughly washing the
wells three times with sterile PBS (0.15 M NaCl, 0.01 M
phosphate buffer, pH 7.2). Afterwards, the compounds, at
the same concentrations used in the planktonic assays, were
added to the wells, and the plates were incubated for further
48 h at 37◦C. The metabolic activity was then evaluated using
a colorimetric assay that measures the metabolic reduction
of 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)
carbonyl]-2H-tetrazolium hydroxide (XTT; Sigma-Aldrich) to a
water-soluble, brown formazan product (Peeters et al., 2008). The
biofilm MIC (bMIC) for each compound was established as the
minimal concentration capable of inhibiting 50% of metabolic
activity when compared to compound-free wells (Ziccardi et al.,
2015).
Statistics
All the experiments were performed in triplicate and in
three independent experimental sets. Statistical differences
were analyzed by one-way ANOVA and Student’s
t-test, using GraphPad Prism version 5.0 software.
In all analyses, P < 0.05 were considered statistically
significant.
RESULTS
Chelate Synthesis
With the exceptions of {[Cu(3,6,9-tdda)(phen)2]3H2O.EtOH}n
(7) and [Ag2(3,6,9-tdda)(phen)4].EtOH (16), all of the other
copper(II), manganese(II) and silver(I) chelates were prepared
and characterized as previously described in the material and
methods section. The formulation of chelate 7 was established
using elemental analysis, IR spectroscopy and magnetic
susceptibility measurements. Chelate 16 was characterized and
formulated based on satisfactory elemental analyses and its
IR and 1H-NMR spectra. The chemical structures of chelates
1–18 are presented in Figure 1 (in cases where exact solid state
structures have not been established using X-ray crystallography
tentative structures have been assigned).
Effects of Test Compounds on Planktonic
Fungal Growth and Their Toxicity Toward
Mammalian Cells
The capacities of the metal chelates, 1–18, to inhibit the viability
of the nine clinical isolates belonging to the C. haemulonii
complex are summarized in Table 1. The manganese(II) and
silver(I) chelates significantly inhibited the viability of all the
fungal isolates. With the exceptions of 1, 2, and 4, the copper(II)
complexes also demonstrated moderate to good antifungal
activity. When the isolates where incubated in the presence of
the simple salts CuCl2 and MnCl2, no appreciable effects against
the fungal cells were observed. In contrast, the simple silver
salt, AgNO3, and the metal-free phen and phendione ligands
appreciably deterred fungal growth, although not as much
as most of the manganese(II) and silver(I) chelates. Aqueous
solutions of DMSO, when used at the concentrations used to
make up solutions of the metal chelates, were inactive against all
the fungal isolates (data not shown).
From an analysis of the GM-MIC values (Table 1) calculated
for each copper(II) chelate across all of the nine isolates of
C. haemulonii complex, {[Cu(3,6,9-tdda)(phen)2]3H2O.EtOH}n
(7) showed the best anti-Candida activity (GM-MIC= 3.37µM).
[Mn2(oda)(phen)4(H2O)2][Mn2(oda)(phen)4(oda)2].4H2O (13)
was the most active of the manganese(II) compounds (GM-
MIC = 0.87 µM), and this was superseded by the silver(I)
compounds, [Ag2(phen)3(udda)].3H2O (18) and [Ag2(3,6,9-
tdda)(phen)4].EtOH (16) (GM-MIC = 0.26 and 0.83 µM,
respectively). Indeed, all of the silver(I) chelates were more active
than the simple silver(I) salt, AgNO3 (3.87 µM). In general,
metal-free phen was∼2-fold more active than phendione.
The calculated GM-MIC values against each of the fungal
species showed some degree of variation. For instance, the
GM-MIC values of all the copper(II) compounds (excluding
the ones with a GM-MIC value of 32 mg/L or higher) were
lower against C. duobushaemulonii species when compared
to the C. haemulonii. The same applies when comparing
C. duobushaemulonii and C. haemulonii var. vulnera, except for
the chelate 6. Contrarily, the silver(I) compounds demonstrated
an opposite trend, with C. duobushaemulonii having the higher
GM-MIC values for all of the chelates when compared to both of
the other Candida species.
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FIGURE 1 | Structures of the copper(II) (1-7), manganese(II) (8-14), and silver(I) (15-18) chelates.
The cytotoxicity of chelates 1–18, the simple metal salts
and the metal-free phen and phendione ligands, was assessed
using the MTT assay with the lung epithelial cell lineage, A549
(Table 2). The manganese(II)-based complexes were extremely
well tolerated by the A549 cells and, consequently, they exhibited
the highest SI values (mean SI range >236.40–48.19) and with
[Mn2(oda)(phen)4(H2O)2][Mn2(oda)(phen)4(oda)2].4H2O (13)
featuring most prominently. Of the remaining test compounds,
only water-soluble [Ag2(phen)3(udda)].3H2O (18) and AgNO3
returned relatively high SI values (mean SI = 56.11 and 27.43,
respectively).
Effects of Test Compounds on
Biofilm-Growing Fungal Cells
In this set of experiments, phen, phendione, AgNO3, and the
metal-based chelates with overall GM-MIC values of 10 µM or
less were selected in order to examine their capacity to disrupt
fungal viability after biofilm formation on a polystyrene surface.
The results (Table 3) revealed that the metal-based compounds
were capable of interfering with the biofilm viability in a manner
that was to some degree dependent upon the fungal isolate
forming the C. haemulonii complex. Overall, the copper(II)
chelate 7, the manganese(II) compounds 11, 13, and 14 and the
silver(I) compound 16 were the most active, presenting bMIC
values below 10 µM. The remaining test complexes had bMIC
values ranging from 12.04 to 28.42 µM. Metal-free phendione
and AgNO3 were the least effective agents. Curiously, against
several of the test compounds the C. haemulonii isolate, LIPCh4,
returned bMIC values exceeding the maximum concentration
tested (512 mg/L).
DISCUSSION
Invasive opportunistic mycoses are associated with high
morbidity and mortality rates, representing serious health
challenges and creating a significant burden for both patients
and health care systems due to the elevated treatment costs
(Caggiano et al., 2015). The reduced number of available effective
antifungal drugs and the increasing emergence of resistance
profiles have indubitably limited the treatment options of such
infections (Abu-Elteen and Hamad, 2012; Almeida et al., 2012;
Muro et al., 2012; Ramos et al., 2015; Sanguinetti et al., 2015).
The severe difficulties encountered in the treatment of infections
caused by theC. haemulonii complex obviates the need to explore
alternative therapeutic approaches.
The antimicrobial capabilities of metals have been harnessed
for centuries, with historical applications in water and food
preservation, agriculture and medicine (Lemire et al., 2013).
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TABLE 2 | Cytotoxicity and selectivity index values of the test compounds.
Compounds A549 (CC50) C. haemulonii (SI)* C. haemulonii
var. vulnera (SI)
C. duobushaemulonii (SI) Overall mean (SI)
1,10-phenanthroline (phen) 4.30 4.30 5.42 4.30 4.67
1,10-phenanthroline-5,6-dione (phendione) 2.02 1.01 1.01 0.80 0.94
CuCl2 123.68 >3.87 >3.87 >3.87 >3.87
MnCl2 133.76 >4.18 >4.18 >4.18 >4.18
AgNO3 16.98 21.39 33.96 26.95 27.43
COPPER(II) CHELATES
[Cu(ph)(phen)(H2O)2] (1) 0.53 <0.02 <0.02 <0.02 <0.02
[Cu(ph)(phen)2].3H2O.2EtOH (2) 1.93 <0.06 <0.06 <0.06 <0.06
[Cu(isoph)(phen)2].6H2O.EtOH (3) 0.89 0.09 0.14 0.18 0.14
[{Cu(phen)2}2(terph)](terph).13.5H2O.2EtOH (4) 3.86 <0.12 0.12 <0.12 ND
[Cu2(oda)(phen)4](ClO4)2.2.76H2O.EtOH (5) 0.98 0.10 0.10 0.12 0.11
[Cu(phendione)3](ClO4)2.4H2O (6) 0.68 0.04 0.11 0.09 0.08
{[Cu(3,6,9-tdda)(phen)2].3H2O.EtOH}n (7) 1.06 0.33 0.42 0.53 0.43
MANGANESE(II) CHELATES
[Mn(ph)(phen)(H2O)2] (8) 234.51 46.53 58.63 46.53 50.56
[Mn(ph)(phen)2(H2O)].4H2O (9) 259.34 129.67 129.67 129.67 129.67
[Mn2(isoph)2(phen)3].4H2O (10) 255.87 40.30 63.97 40.30 48.19
{[Mn(phen)2(H2O)2]}2(isoph)2(phen).12H2O (11) 251.76 99.91 99.91 99.91 99.91
[Mn(tereph)(phen)2].5H2O (12) 251.94 62.99 62.99 62.99 62.99
[Mn2(oda)(phen)4(H2O)2][Mn2(oda)(phen)4(oda)2]4H2O (13) >512 >256 >256 >203.19 >236.40
{[Mn(3,6,9-tdda)(phen)2].3H2O.EtOH}n (14) 261.67 130.84 130.84 82.42 114.70
SILVER(I) CHELATES
[Ag(phendione)2]ClO4(15) 3.76 3.76 2.98 1.88 2.87
[Ag2(3,6,9-tdda)(phen)4].EtOH (16) 2.21 2.21 2.78 1.75 2.25
[Ag(phen)2]ClO4 (17) 2.07 2.07 3.29 1.30 2.22
[Ag2(phen)3(udda)].3H2O (18) 13.63 86.55 54.52 27.26 56.11
*Selectivity indexes (SI) were calculated using the formula CC50/GM-MIC. Adenocarcinomic human alveolar basal epithelial A549 cells were used for the cytotoxicity assays and the
CC50 values are expressed as mg/L. GM is the geometric mean of the SI values of the compounds against each species of the Candida haemulonii complex.
Inorganic medicinal chemistry, an interdisciplinary research
field, is advancing our knowledge ofmetal toxicity and facilitating
the design of metal-containing compounds as effective and
targeted antimicrobials, offering a realistic alternative to
organic antibiotics (Lemire et al., 2013). We have previously
demonstrated that Cu(II), Mn(II), and Ag(I) chelates containing
phen-type ligands exhibit antifungal activity against clinical
isolates of C. albicans (Devereux et al., 2000; Geraghty et al.,
2000; Coyle et al., 2003; McCann et al., 2004; Creaven
et al., 2009). Therefore, we were prompted to assess the
antifungal chemotherapeutic potential of this class of metal
chelate against the highly resistant C. haemulonii species
complex. To this end, we tested 16 known chelates (1–6,
8–15, 17, and 18) and 2 new ones (7 and 16), containing
either neutral phen or phendione ligands and coordinated or
uncoordinated dicarboxylate or perchlorate anions (Figure 1).
The complexes, along with the “metal-free” phen and phendione
and simple metal salts, were assessed for their ability to
inhibit the growth of nine clinical strains of the three
species that make up the C. haemulonii complex against both
planktonic and biofilm lifestyles. Potent antifungal activity
was observed for a number of the test compounds, with
the order of planktonic growth inhibition being; chelate
18>16>13>17>11>15>9>14>7>10>12>5>3>6>8. When
the chelates are classified according to the nature of the central
metal ion, the silver(I) compounds (15–18) have the best overall
growth inhibitory effect, followed by those of manganese(II)
(8–14).
While the simple metal salts, CuCl2 and MnCl2, were not
able to effectively reduce the fungal cell proliferation, the
silver(I) salt exhibited good inhibitory capability. It should
be noted that AgNO3 is a well-established source of Ag
+
ions, which are well known to have potent antifungal activity
(Lemire et al., 2013). Thus, it is fair to assume that the type
of metal ion present in the compounds may directly impact
their antifungal capability (Devereux et al., 2000; McCann
et al., 2004). In contrast, the uncoordinated dicarboxylic acid
ligands (e.g., phthalic, isothphalic, terethphalicoctanedioic, and
3,6,9-trioxaundecanedioic acids) are known to not exhibit anti-
Candida capability, and our results indicate that these ligands also
have no effect on the proliferation of the fungal isolates employed
in the current study (data not shown) (Devereux et al., 2000).
The metal-free (uncoordinated) phen and phendione also had a
potent inhibitory effect on the C. haemulonii species complex,
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which is in agreement with results obtained from other studies
reporting the activity of phen against Candida species such as
C. tropicalis, C. krusei and C. glabrata (Geraghty et al., 2000;
McCann et al., 2000, 2004, 2012; Coyle et al., 2003). It should
be noted that, although metal-free phen and phendione and
the Ag+ ions (from AgNO3) exhibited antifungal activities, the
silver(I) chelates (15–18) were able to induce a more pronounced
inhibitory antifungal effect based on their overall GM-MIC
(µM values). The same observation applies to the copper(II), 7,
and the manganese(II), 9, 10, 11, 13, and 14, chelates, which
were more active in inhibiting cellular proliferation than both
the corresponding simple metal salt and the “metal-free” phen
and phendione ligands, indicating that the chelates are much
superior antimicrobial agents. Previous studies into the mode
of action of these chelates revealed their potential to disrupt
mitochondrial activity and respiration processes, restriction of
cell growth by interfering with protein synthesis, cleavage of
proteins, DNA interaction/cleavage and epigenetic influences
(Devereux et al., 2000; Metcalfe and Thomas, 2003; McCann
et al., 2012; Kharissova et al., 2014). These mechanisms of
action of the metal chelates differ from those of the azole
and polyene drug classes commonly used to treat fungal
infections, and they offer the prospect of developing inorganic
drugs capable of overcoming the resistance traits that make
the treatment of C. haemulonii species complex infection so
difficult.
An ability to form biofilms is an acknowledged virulence
factor of microorganisms, which protects them from the host’s
immune system and also from the action of antifungal drugs
(Mello et al., 2017). Administered drugs experience reduced
access to the pathogen as a result of the presence of a biofilm
matrix composed of polysaccharides, carbohydrates, proteins and
DNA. Besides that, the presence of a biofilm on an implanted
medical device may become a reservoir of pathogenic cells that
are released to the bloodstream, resulting in dissemination to
internal sites and organs (Bujdáková, 2016; Ramos et al., 2017).
Candida strains with an inherent ability to establish a biofilm are
associated with a higher mortality rate when compared to strains
incapable of biofilm formation (Peeters et al., 2008; Garcia-
Vidal et al., 2013; Kawai et al., 2015; Rajendran et al., 2016).
The C. haemulonii complex has a considerable biofilm-forming
capacity (Bujdáková, 2016; Ramos et al., 2017) and, curiously,
the presence of a central venous catheter was mentioned in all
of the fungemia case reports regarding these species between
2002 and 2010 (Khan et al., 2007; Almeida et al., 2012; Cendejas-
Bueno et al., 2012; Muro et al., 2012). One documented case also
describes an outbreak in neonatal patients who were receiving
total parenteral nutrition (Kim et al., 2009).
Metal-free phen and phendione, AgNO3 and the chelates 3
and 5–18, which all had shown good in vitro activity against
planktonic growth of the three fungal species forming the
C. haemulonii complex, were also assessed for their capacity
to inhibit the growth of cells in a mature biofilm. The most
active were the manganese(II) chelates 13 (3.5 µM), 14 (4.7 µM)
and the silver(I) complex 16 (5.2 µM). Two more compounds
were also very effective against the biofilm, the manganese(II)
complex 11 and the copper(II) complex 7. A clear reduction in
the antifungal capacity of the test compounds was clearly evident
on going from planktonic to biofilm cells. The most pronounced
decrease in activity was detected for [Ag2(phen)3(udda)].3H2O
(18) (46.3-fold), followed by AgNO3 (43.8-fold), 17 (12.3-fold),
15 (11.8-fold) and complex 16 (6.3-fold). It is interesting that
chelate 18, which was the most active against planktonic cell
growth, showed the highest reduction in activity. A degree of
variation in compound tolerance amongst the fungal constituent
strains of the biofilm is noticeable, with C. haemulonii LIPCh4
being the most defiant. The data obtained in the current study
demonstrates that although the test compounds were less active
against a biofilm, some had impressively low overall GM-bMIC
values, such as chelates 13 (3.5 µM), 14 (4.7 µM), 16 (5.2 µM),
and 11 (5.3 µM).
In a global scale, there is an urgent demand for the discovery
of new therapies with effective, safe and cheap drugs to
be used as alternative treatment against (multi)drug-resistant
pathogens. In this line of thinking, copper(II), manganese(II)
and silver(I) chelates containing phen and phendione ligands
are relatively cheap and easy to prepare and they clearly have
significant antifungal chemotherapeutic potential against the
highly resistant C. haemulonii complex.
CONCLUSIONS
In summary, the results from the present study indicate that
copper(II), manganese(II) and silver(I) chelates containing phen
and phendione ligands are capable of inhibiting planktonic
and biofilm growth of the three fungal species that comprise
the C. haemulonii complex, and which are known to be
highly resistant to the most commonly used antifungals.
In particular, a number of the manganese(II) and silver(I)
complexes were very effective at preventing cellular proliferation
and the manganese(II) complexes demonstrated relatively low
cytotoxicity toward the mammalian cell line, A549, indicating
very favorable selectivity for the C. haemulonii species complex.
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